These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Standardization of organoid culture in cancer research. Zhou C; Wu Y; Wang Z; Liu Y; Yu J; Wang W; Chen S; Wu W; Wang J; Qian G; He A Cancer Med; 2023 Jul; 12(13):14375-14386. PubMed ID: 37081739 [TBL] [Abstract][Full Text] [Related]
4. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges. Li J; Liu J; Xia W; Yang H; Sha W; Chen H Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190 [TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank. Zhou Z; Cong L; Cong X Front Oncol; 2021; 11():762184. PubMed ID: 35036354 [TBL] [Abstract][Full Text] [Related]
6. Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research. Nguyen R; Da Won Bae S; Qiao L; George J Cancer Lett; 2021 Jun; 508():13-17. PubMed ID: 33771683 [TBL] [Abstract][Full Text] [Related]
7. Progress in patient-derived liver cancer cell models: a step forward for precision medicine. Zhang Z; Hui L Acta Biochim Biophys Sin (Shanghai); 2023 Nov; 55(11):1707-1717. PubMed ID: 37766458 [TBL] [Abstract][Full Text] [Related]
8. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474 [TBL] [Abstract][Full Text] [Related]
9. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Broutier L; Mastrogiovanni G; Verstegen MM; Francies HE; Gavarró LM; Bradshaw CR; Allen GE; Arnes-Benito R; Sidorova O; Gaspersz MP; Georgakopoulos N; Koo BK; Dietmann S; Davies SE; Praseedom RK; Lieshout R; IJzermans JNM; Wigmore SJ; Saeb-Parsy K; Garnett MJ; van der Laan LJ; Huch M Nat Med; 2017 Dec; 23(12):1424-1435. PubMed ID: 29131160 [TBL] [Abstract][Full Text] [Related]
10. Organoid factory: The recent role of the human induced pluripotent stem cells (hiPSCs) in precision medicine. Novelli G; Spitalieri P; Murdocca M; Centanini E; Sangiuolo F Front Cell Dev Biol; 2022; 10():1059579. PubMed ID: 36699015 [TBL] [Abstract][Full Text] [Related]
11. Automation of Organoid Cultures: Current Protocols and Applications. Louey A; Hernández D; Pébay A; Daniszewski M SLAS Discov; 2021 Oct; 26(9):1138-1147. PubMed ID: 34167363 [TBL] [Abstract][Full Text] [Related]
12. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer. Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y Front Immunol; 2023; 14():1180184. PubMed ID: 37334366 [TBL] [Abstract][Full Text] [Related]
13. Drug screening by uniform patient derived colorectal cancer hydro-organoids. Jung YH; Choi DH; Park K; Lee SB; Kim J; Kim H; Jeong HW; Yang JH; Kim JA; Chung S; Min BS Biomaterials; 2021 Sep; 276():121004. PubMed ID: 34273688 [TBL] [Abstract][Full Text] [Related]
14. Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy. Wang J; Chen C; Wang L; Xie M; Ge X; Wu S; He Y; Mou X; Ye C; Sun Y Front Oncol; 2022; 12():872531. PubMed ID: 35449581 [TBL] [Abstract][Full Text] [Related]
15. Patient-derived cancer organoids for drug screening: Basic technology and clinical application. Ren X; Chen W; Yang Q; Li X; Xu L J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719 [TBL] [Abstract][Full Text] [Related]
16. Liver Organoids as an In Vitro Model to Study Primary Liver Cancer. De Siervi S; Turato C Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901961 [TBL] [Abstract][Full Text] [Related]
17. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434 [TBL] [Abstract][Full Text] [Related]
18. Organoid engineering with microfluidics and biomaterials for liver, lung disease, and cancer modeling. Kim SK; Kim YH; Park S; Cho SW Acta Biomater; 2021 Sep; 132():37-51. PubMed ID: 33711526 [TBL] [Abstract][Full Text] [Related]
19. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer. Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147 [TBL] [Abstract][Full Text] [Related]
20. Promises and Challenges of Organoid-Guided Precision Medicine. Bose S; Clevers H; Shen X Med; 2021 Sep; 2(9):1011-1026. PubMed ID: 34617071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]